Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$5.34 - $12.79 $21,360 - $51,160
-4,000 Reduced 5.69%
66,300 $699,000
Q2 2022

Aug 11, 2022

BUY
$5.1 - $9.74 $358,530 - $684,722
70,300 New
70,300 $382,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $110M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.